| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lenalidomide after stem-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2012
|
6.24
|
|
2
|
Defining the intensity of conditioning regimens: working definitions.
|
Biol Blood Marrow Transplant
|
2009
|
6.22
|
|
3
|
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
|
Sci Transl Med
|
2014
|
5.60
|
|
4
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
5
|
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
|
Blood
|
2004
|
3.70
|
|
6
|
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
|
Blood
|
2002
|
3.56
|
|
7
|
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
3.52
|
|
8
|
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
|
J Clin Oncol
|
2010
|
2.99
|
|
9
|
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
|
Lancet Oncol
|
2011
|
2.78
|
|
10
|
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.
|
Blood
|
2010
|
2.73
|
|
11
|
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
2.64
|
|
12
|
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
|
J Clin Oncol
|
2010
|
2.58
|
|
13
|
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.
|
Blood
|
2007
|
2.47
|
|
14
|
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
|
Cancer
|
2010
|
2.41
|
|
15
|
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
|
Blood
|
2006
|
2.31
|
|
16
|
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
|
Am J Hematol
|
2014
|
2.26
|
|
17
|
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.
|
J Clin Oncol
|
2002
|
2.18
|
|
18
|
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
|
Cancer
|
2009
|
2.15
|
|
19
|
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
|
J Clin Oncol
|
2010
|
2.09
|
|
20
|
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
|
Blood
|
2011
|
2.07
|
|
21
|
Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation.
|
J Pain Symptom Manage
|
2012
|
1.97
|
|
22
|
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
|
Biol Blood Marrow Transplant
|
2008
|
1.96
|
|
23
|
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.
|
J Clin Oncol
|
2010
|
1.91
|
|
24
|
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
|
Biol Blood Marrow Transplant
|
2009
|
1.87
|
|
25
|
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.
|
Blood
|
2009
|
1.86
|
|
26
|
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.85
|
|
27
|
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.
|
Haematologica
|
2003
|
1.82
|
|
28
|
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.
|
Transplantation
|
2009
|
1.76
|
|
29
|
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
|
Biol Blood Marrow Transplant
|
2007
|
1.74
|
|
30
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.72
|
|
31
|
Authors' reply to Tendas et al.
|
J Pain Symptom Manage
|
2013
|
1.66
|
|
32
|
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
|
Blood
|
2009
|
1.59
|
|
33
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.56
|
|
34
|
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.55
|
|
35
|
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
|
Leuk Lymphoma
|
2014
|
1.50
|
|
36
|
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.50
|
|
37
|
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
|
Exp Hematol
|
2004
|
1.50
|
|
38
|
Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation.
|
Cancer
|
2007
|
1.45
|
|
39
|
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.42
|
|
40
|
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.
|
Blood
|
2004
|
1.42
|
|
41
|
Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia.
|
Am J Hematol
|
2005
|
1.40
|
|
42
|
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
|
Biol Blood Marrow Transplant
|
2010
|
1.38
|
|
43
|
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.33
|
|
44
|
A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.32
|
|
45
|
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
|
Biol Blood Marrow Transplant
|
2009
|
1.31
|
|
46
|
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.
|
J Clin Oncol
|
2004
|
1.28
|
|
47
|
Relapse after allogeneic hematopoietic cell therapy.
|
Biol Blood Marrow Transplant
|
2009
|
1.27
|
|
48
|
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.
|
Blood
|
2005
|
1.27
|
|
49
|
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
|
Biol Blood Marrow Transplant
|
2013
|
1.25
|
|
50
|
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.
|
Haematologica
|
2010
|
1.25
|
|
51
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2010
|
1.23
|
|
52
|
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
|
Blood
|
2006
|
1.19
|
|
53
|
Quantitative sensory findings in patients with bortezomib-induced pain.
|
J Pain
|
2006
|
1.16
|
|
54
|
Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.
|
Biol Blood Marrow Transplant
|
2011
|
1.15
|
|
55
|
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
56
|
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
57
|
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
1.13
|
|
58
|
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units.
|
Br J Haematol
|
2002
|
1.13
|
|
59
|
Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2008
|
1.11
|
|
60
|
Hyperacute GVHD: risk factors, outcomes, and clinical implications.
|
Blood
|
2007
|
1.10
|
|
61
|
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.
|
Hematology Am Soc Hematol Educ Program
|
2000
|
1.10
|
|
62
|
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
63
|
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
|
Biol Blood Marrow Transplant
|
2011
|
1.09
|
|
64
|
Symptom burden after autologous stem cell transplantation for multiple myeloma.
|
Cancer
|
2008
|
1.09
|
|
65
|
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
|
Biol Blood Marrow Transplant
|
2011
|
1.09
|
|
66
|
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.
|
Am J Hematol
|
2009
|
1.07
|
|
67
|
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
1.06
|
|
68
|
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
69
|
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
|
Cancer
|
2004
|
1.04
|
|
70
|
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
|
Blood
|
2012
|
1.03
|
|
71
|
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Haematologica
|
2009
|
1.02
|
|
72
|
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
|
J Clin Oncol
|
2005
|
1.02
|
|
73
|
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
|
Blood
|
2010
|
1.01
|
|
74
|
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
|
Leuk Lymphoma
|
2011
|
1.01
|
|
75
|
Durable remission with salvage second autotransplants in patients with multiple myeloma.
|
Cancer
|
2011
|
1.01
|
|
76
|
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
|
Cancer
|
2007
|
1.00
|
|
77
|
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
|
Cancer
|
2010
|
0.98
|
|
78
|
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
0.97
|
|
79
|
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.96
|
|
80
|
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
|
Biol Blood Marrow Transplant
|
2008
|
0.93
|
|
81
|
Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.
|
Biol Blood Marrow Transplant
|
2008
|
0.93
|
|
82
|
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.
|
J Clin Oncol
|
2010
|
0.93
|
|
83
|
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
|
Br J Haematol
|
2007
|
0.93
|
|
84
|
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.
|
Biol Blood Marrow Transplant
|
2007
|
0.92
|
|
85
|
Drug safety evaluation of defibrotide.
|
Expert Opin Drug Saf
|
2012
|
0.92
|
|
86
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
0.91
|
|
87
|
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
|
Biol Blood Marrow Transplant
|
2010
|
0.90
|
|
88
|
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters.
|
Blood
|
2004
|
0.89
|
|
89
|
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.
|
Biol Blood Marrow Transplant
|
2002
|
0.88
|
|
90
|
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
|
Blood
|
2007
|
0.87
|
|
91
|
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
|
Biol Blood Marrow Transplant
|
2010
|
0.87
|
|
92
|
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
|
Curr Opin Oncol
|
2012
|
0.87
|
|
93
|
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
|
Am J Hematol
|
2012
|
0.86
|
|
94
|
Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
95
|
Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
|
Semin Hematol
|
2006
|
0.85
|
|
96
|
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
|
Oncologist
|
2003
|
0.85
|
|
97
|
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.85
|
|
98
|
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation.
|
Transfusion
|
2011
|
0.84
|
|
99
|
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
|
Leuk Lymphoma
|
2004
|
0.84
|
|
100
|
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.
|
Ther Adv Hematol
|
2012
|
0.84
|
|
101
|
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
|
Br J Haematol
|
2006
|
0.83
|
|
102
|
Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.
|
Ann Diagn Pathol
|
2006
|
0.83
|
|
103
|
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
|
Clin Lymphoma Myeloma
|
2009
|
0.83
|
|
104
|
The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
105
|
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
|
Biol Blood Marrow Transplant
|
2007
|
0.82
|
|
106
|
Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.
|
Eur J Haematol
|
2003
|
0.82
|
|
107
|
Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.
|
Leuk Lymphoma
|
2014
|
0.81
|
|
108
|
A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.
|
Leuk Lymphoma
|
2014
|
0.81
|
|
109
|
Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant.
|
J Natl Compr Canc Netw
|
2008
|
0.80
|
|
110
|
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2006
|
0.80
|
|
111
|
The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.
|
Am J Hematol
|
2010
|
0.80
|
|
112
|
Stem cell transplantation for multiple myeloma: current status and future directions.
|
Curr Hematol Rep
|
2004
|
0.79
|
|
113
|
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
|
Cancer
|
2003
|
0.79
|
|
114
|
A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas.
|
J Blood Med
|
2010
|
0.78
|
|
115
|
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
|
J Natl Cancer Inst
|
2009
|
0.78
|
|
116
|
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2004
|
0.78
|
|
117
|
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
|
Biol Blood Marrow Transplant
|
2010
|
0.78
|
|
118
|
Transplantation remains significantly underused.
|
Clin Adv Hematol Oncol
|
2014
|
0.78
|
|
119
|
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.
|
Oncology (Williston Park)
|
2003
|
0.78
|
|
120
|
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.
|
Biol Blood Marrow Transplant
|
2007
|
0.78
|
|
121
|
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
|
Expert Rev Hematol
|
2014
|
0.77
|
|
122
|
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
|
Am J Hematol
|
2013
|
0.77
|
|
123
|
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.
|
Leuk Lymphoma
|
2011
|
0.77
|
|
124
|
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
|
Am J Hematol
|
2012
|
0.77
|
|
125
|
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.
|
Biol Blood Marrow Transplant
|
2012
|
0.77
|
|
126
|
200 mg/m(2) melphalan--the gold standard for multiple myeloma.
|
Nat Rev Clin Oncol
|
2010
|
0.77
|
|
127
|
The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
128
|
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
|
Clin Adv Hematol Oncol
|
2007
|
0.76
|
|
129
|
The current landscape of multiple myeloma treatment.
|
Leuk Res
|
2008
|
0.76
|
|
130
|
Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy.
|
Cancer Treat Res
|
2002
|
0.76
|
|
131
|
Graft-versus-host disease: have we solved the problem?
|
J Clin Oncol
|
2012
|
0.75
|
|
132
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
133
|
Epidermodysplasia verruciformis in the setting of graft-versus-host disease.
|
J Am Acad Dermatol
|
2007
|
0.75
|
|
134
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
135
|
Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab.
|
Leuk Lymphoma
|
2003
|
0.75
|
|
136
|
Nonmyeloablative reduced-intensity transplantation in multiple myeloma.
|
Semin Oncol
|
2004
|
0.75
|
|
137
|
Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?
|
Clin Lymphoma Myeloma
|
2009
|
0.75
|
|
138
|
Hepatic haematoma after allogeneic transplantation.
|
Br J Haematol
|
2003
|
0.75
|
|
139
|
Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution.
|
Am J Hematol
|
2007
|
0.75
|
|
140
|
Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions.
|
Semin Oncol
|
2003
|
0.75
|
|
141
|
Assessing response of therapy for acute and chronic graft-versus-host disease.
|
Expert Rev Hematol
|
2013
|
0.75
|